Michael O'Dwyer

13PUBLICATIONS
36CO-AUTHORS
Predictive and prognostic markersNgā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 07, 2026
SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver.

|Feb 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.

Thierry Facon, Philippe Moreau, Katja Weisel

|Jan 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.

Philippe Moreau, Thierry Facon, Saad Z Usmani

|Mar 16, 2022
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.

John Daly, Subhashis Sarkar, Alessandro Natoni

|Sep 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.

Daniel J DeAngelo, Brian A Jonas, Jane L Liesveld

|Apr 03, 2021
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.

Mark Gurney, Michael O'Dwyer

Pageof 3

Frequent Collaborators

3 joint publications

Jinsong Hu

2 joint publications

Robert Z Orlowski

2 joint publications

Alessandro Natoni

2 joint publications

Philippe Moreau